10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.
- 30 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
- 31 Aug 2018 Biomarkers information updated